Loading...
XNASESPR
Market cap433mUSD
Jan 15, Last price  
2.20USD
1D
-1.79%
1Q
4.27%
Jan 2017
-82.43%
IPO
-84.83%
Name

Esperion Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:ESPR chart
P/E
—
P/S
3.73
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
30.97%
Rev. gr., 5y
-8.81%
Revenues
116m
+54.14%
02,00000004,977,012,0000000184,474,000148,364,000227,547,00078,447,00075,475,000116,334,000
Net income
-209m
L-27.30%
-10,670,184-27,576,000-24,931,000-28,726,000-10,817,341-11,741,736-26,088,133-36,375,000-49,784,000-74,978,000-166,988,000-201,810,000-109,022,000-166,189,000-318,824,000-287,817,000-209,248,000
CFO
-135m
L-22.50%
-7,852,572-17,954,000-22,767,000-26,564,000-9,068,725-10,808,567-18,113,361-32,021,000-38,156,000-47,730,000-131,302,000-148,638,000-70,341,000-85,177,000-263,809,000-174,827,000-135,487,000
Earnings
Feb 25, 2025

Profile

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
URL
https://www.esperion.com/
IPO date
Jun 24, 2013
Employees
199
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
116,334
54.14%
75,475
-3.79%
Cost of revenue
271,897
254,976
Unusual Expense (Income)
NOPBT
(155,563)
(179,501)
NOPBT Margin
Operating Taxes
54,158
Tax Rate
NOPAT
(155,563)
(233,659)
Net income
(209,248)
-27.30%
(287,817)
-9.73%
Dividends
Dividend yield
Proceeds from repurchase of equity
56,876
90,849
BB yield
-18.45%
-21.96%
Debt
Debt current
36,381
384
Long-term debt
509,139
261,613
Deferred revenue
Other long-term liabilities
218,845
Net debt
463,272
95,136
Cash flow
Cash from operating activities
(135,487)
(174,827)
CAPEX
Cash from investing activities
42,500
8,104
Cash from financing activities
50,460
32,606
FCF
(159,038)
(184,177)
Balance
Cash
82,248
124,775
Long term investments
42,086
Excess cash
76,431
163,087
Stockholders' equity
(1,549,166)
(1,339,963)
Invested Capital
1,635,119
479,720
ROIC
ROCE
EV
Common stock shares outstanding
103,107
66,407
Price
2.99
-52.01%
6.23
24.60%
Market cap
308,289
-25.48%
413,717
186.28%
EV
771,561
508,853
EBITDA
(155,399)
(179,001)
EV/EBITDA
Interest
58,976
56,810
Interest/NOPBT